PRKN and acute respiratory distress syndrome: Therapeutic strategies targeting specific regulatory axes—such as PINK1-Parkin in ALI/ARDS or FUNDC1 in hypoxic fibrosis—show promise in preclinical models, supported by pharmacological agents ranging from natural compounds (melatonin, resveratrol) to TCM formulations.